

Jur Ten Berg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/92325/publications.pdf>

Version: 2024-02-01

76
papers

7,152
citations

218677

26
h-index

79698

73
g-index

76
all docs

76
docs citations

76
times ranked

7416
citing authors

#	ARTICLE	IF	CITATIONS
1	Antithrombotic therapy according to baseline bleeding risk in patients with atrial fibrillation undergoing percutaneous coronary intervention: applying the PRECISE-DAPT score in RE-DUAL PCI. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 216-226.	3.0	23
2	Efficacy and safety of glycoprotein IIb/IIIa inhibitors in addition to P2Y ₁₂ inhibitors in ST-segment elevation myocardial infarction: A subanalysis of the POPular Genetics trial. <i>Catheterization and Cardiovascular Interventions</i> , 2022, 99, 676-685.	1.7	3
3	Cost Effectiveness of a CYP2C19 Genotype-Guided Strategy in Patients with Acute Myocardial Infarction: Results from the POPular Genetics Trial. <i>American Journal of Cardiovascular Drugs</i> , 2022, 22, 195-206.	2.2	13
4	Defining optimal antithrombotic therapy post-TAVI: the contribution of ATLANTIS. <i>European Heart Journal</i> , 2022, 43, 2798-2800.	2.2	5
5	External validation of the GRACE risk score and the risk-treatment paradox in patients with acute coronary syndrome. <i>Open Heart</i> , 2022, 9, e001984.	2.3	10
6	Impact of Coronavirus Disease 2019 (COVID-19) Outbreak on Acute Admissions at the Emergency and Cardiology Departments Across Europe. <i>American Journal of Medicine</i> , 2021, 134, 482-489.	1.5	53
7	Patient-tailored antithrombotic therapy following percutaneous coronary intervention. <i>European Heart Journal</i> , 2021, 42, 1038-1046.	2.2	28
8	Pre-Hospital Antiplatelet Therapy for STEMI Patients Undergoing Primary Percutaneous Coronary Intervention: What We Know and What Lies Ahead. <i>Thrombosis and Haemostasis</i> , 2021, 121, 1562-1573.	3.4	12
9	Clopidogrel Versus Ticagrelor or Prasugrel After Primary Percutaneous Coronary Intervention According to CYP2C19 Genotype. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e009434.	3.9	14
10	Aspirin Alone Versus Dual Antiplatelet Therapy After Transcatheter Aortic Valve Implantation: A Systematic Review and Patient-Level Meta-Analysis. <i>Journal of the American Heart Association</i> , 2021, 10, e019604.	3.7	13
11	Management of antithrombotic therapy in patients undergoing transcatheter aortic valve implantation: a consensus document of the ESC Working Group on Thrombosis and the European Association of Percutaneous Cardiovascular Interventions (EAPCI), in collaboration with the ESC Council on Valvular Heart Disease. <i>European Heart Journal</i> , 2021, 42, 2265-2269.	2.2	81
12	Periprocedural Course of Proteinuria After Transcatheter Aortic Valve Implantation: Substudy From the POPular TAVI Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010404.	3.9	0
13	Clopidogrel in noncarriers of CYP2C19 loss-of-function alleles versus ticagrelor in elderly patients with acute coronary syndrome: A pre-specified sub analysis from the POPular Genetics and POPular Age trials CYP2C19 alleles in elderly patients. <i>International Journal of Cardiology</i> , 2021, 334, 10-17.	1.7	4
14	Venous and arterial thromboembolic disease in COVID-19. <i>Journal of Thrombosis and Thrombolysis</i> , 2021, 52, 1007-1009.	2.1	2
15	Is there a benefit for CYP2C19 genotype-guided antiplatelet treatment in elderly acute coronary syndrome patients?. <i>Pharmacogenomics</i> , 2021, 22, 727-730.	1.3	0
16	Long-term residual cardiovascular risk after acute coronary syndrome: antithrombotic treatment options. <i>Netherlands Heart Journal</i> , 2021, , 1.	0.8	5
17	Antithrombotic therapy in patients undergoing trans catheter aortic valve implantation. <i>European Heart Journal</i> , 2021, 42, 3205-3206.	2.2	2
18	Antithrombotic Therapy After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2021, 14, 1688-1703.	2.9	31

#	ARTICLE	IF	CITATIONS
19	Factor V Leiden and the Risk of Bleeding in Patients With Acute Coronary Syndromes Treated With Antiplatelet Therapy: Pooled Analysis of 3 Randomized Clinical Trials. <i>Journal of the American Heart Association</i> , 2021, 10, e021115.	3.7	2
20	Known or new atrial fibrillation in patients with acute coronary syndrome: what's the difference?. <i>European Heart Journal</i> , 2021, 42, 4562-4564.	2.2	4
21	Dabigatran Dual Therapy Versus Warfarin Triple Therapy Post PCI in Patients With Atrial Fibrillation. <i>Journal of the American College of Cardiology</i> , 2020, 75, 238-240.	2.8	2
22	Comparison of the Effect of Age (< 75 Versus ≥ 75) on the Efficacy and Safety of Dual Therapy (Dabigatran + Clopidogrel or Ticagrelor) Versus Triple Therapy (Warfarin + Aspirin + Clopidogrel or) <small>1.6</small> <small>0.0</small> <small>13</small> <small>rgBT / O</small>		
23	A randomized, double-blind, placebo-controlled trial investigating the effect of ticagrelor on saphenous vein graft patency in patients undergoing coronary artery bypass grafting surgery. Rationale and design of the POPular CABG trial. <i>American Heart Journal</i> , 2020, 220, 237-245.	2.7	5
24	Pharmacodynamics, pharmacokinetics, and safety of single-dose subcutaneous administration of selatogrel, a novel P2Y12 receptor antagonist, in patients with chronic coronary syndromes. <i>European Heart Journal</i> , 2020, 41, 3132-3140.	2.2	52
25	Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of Ticagrelor in STEMI: A Subanalysis of the ATLANTIC Trial. <i>Thrombosis and Haemostasis</i> , 2020, 120, 065-074.	3.4	11
26	Ticagrelor Versus Clopidogrel in Older Patients with NSTEMI-ACS Using Oral Anticoagulation: A Sub-Analysis of the POPular Age Trial. <i>Journal of Clinical Medicine</i> , 2020, 9, 3249.	2.4	5
27	Rationale and Design of the Future Optimal Research and Care Evaluation in Patients with Acute Coronary Syndrome (FORCE-ACS) Registry: Towards Personalized Medicine in Daily Clinical Practice. <i>Journal of Clinical Medicine</i> , 2020, 9, 3173.	2.4	6
28	Association of Factor V Leiden With Subsequent Atherothrombotic Events. <i>Circulation</i> , 2020, 142, 546-555.	1.6	11
29	Effect of Adding Ticagrelor to Standard Aspirin on Saphenous Vein Graft Patency in Patients Undergoing Coronary Artery Bypass Grafting (POPular CABG). <i>Circulation</i> , 2020, 142, 1799-1807.	1.6	37
30	Aspirin with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. <i>New England Journal of Medicine</i> , 2020, 383, 1447-1457.	27.0	228
31	Oral Anticoagulants After Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 2598-2600.	2.9	2
32	Complex clinical scenarios with the use of direct oral anticoagulants in patients with atrial fibrillation: a multidisciplinary expert advisory board. <i>Netherlands Heart Journal</i> , 2020, 28, 504-513.	0.8	1
33	Protamine in Patients Undergoing Transcatheter Aortic Valve Replacement. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1481-1483.	2.9	0
34	Anticoagulation with or without Clopidogrel after Transcatheter Aortic-Valve Implantation. <i>New England Journal of Medicine</i> , 2020, 382, 1696-1707.	27.0	235
35	Personalized P2Y12 Inhibitor Treatment. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 631-633.	2.9	2
36	Reloading When Switching From Ticagrelor or Prasugrel to Clopidogrel Within 7 Days After STEMI. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 663-665.	2.9	1

#	ARTICLE	IF	CITATIONS
37	Optimal Antithrombotic Regimens for Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. <i>JAMA Cardiology</i> , 2020, 5, 582.	6.1	71
38	Derivation, Validation, and Prognostic Utility of a Prediction Rule for Nonresponse to Clopidogrel. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 606-617.	2.9	90
39	Updated Expert Consensus Statement on Platelet Function and Genetic Testing for Guiding P2Y ₁₂ Receptor Inhibitor Treatment in Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1521-1537.	2.9	366
40	Renal Function and Outcomes With Dabigatran Dual Antithrombotic Therapy in Atrial Fibrillation Patients After PCI. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1553-1561.	2.9	9
41	A Genotype-Guided Strategy for Oral P2Y ₁₂ Inhibitors in Primary PCI. <i>New England Journal of Medicine</i> , 2019, 381, 1621-1631.	27.0	431
42	Subsequent Event Risk in Individuals With Established Coronary Heart Disease. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002470.	3.6	17
43	Association of Chromosome 9p21 With Subsequent Coronary Heart Disease Events. <i>Circulation Genomic and Precision Medicine</i> , 2019, 12, e002471.	3.6	22
44	Sex differences in characteristics and outcome in acute coronary syndrome patients in the Netherlands. <i>Netherlands Heart Journal</i> , 2019, 27, 263-271.	0.8	27
45	Dabigatran dual therapy with ticagrelor or clopidogrel after percutaneous coronary intervention in atrial fibrillation patients with or without acute coronary syndrome: a subgroup analysis from the RE-DUAL PCI trial. <i>European Heart Journal</i> , 2019, 40, 1553-1562.	2.2	62
46	Switching of Oral Anticoagulation Therapy After PCI in Patients With Atrial Fibrillation. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 2331-2341.	2.9	8
47	Effect of early tirofiban administration on N-terminal pro-B-type natriuretic peptide level in patients treated with primary percutaneous coronary intervention. <i>Catheterization and Cardiovascular Interventions</i> , 2019, 93, E293-E297.	1.7	3
48	A clinical risk score to identify patients at high risk of very late stent thrombosis. <i>Journal of Interventional Cardiology</i> , 2018, 31, 159-169.	1.2	6
49	2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. <i>European Heart Journal</i> , 2018, 39, 213-260.	2.2	2,246
50	Efficacy and Safety of the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients With Nonvalvular Atrial Fibrillation and Concomitant Aspirin Therapy. <i>Circulation</i> , 2018, 137, 1117-1129.	1.6	37
51	How Long Does It Take for Clopidogrel and Ticagrelor to Inhibit Platelets in Patients Undergoing Primary Percutaneous Coronary Intervention? A Detailed Pharmacodynamic Analysis: Time Course of Platelet Reactivity in STEMI (TOPS). <i>Seminars in Thrombosis and Hemostasis</i> , 2017, 43, 439-446.	2.7	9
52	Effect of Tailored Antiplatelet Therapy to Reduce Recurrent Stent Thrombosis and Cardiac Death After a First Episode of Stent Thrombosis. <i>American Journal of Cardiology</i> , 2017, 119, 1500-1506.	1.6	3
53	Dual Antithrombotic Therapy with Dabigatran after PCI in Atrial Fibrillation. <i>New England Journal of Medicine</i> , 2017, 377, 1513-1524.	27.0	1,099
54	Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials. <i>American Heart Journal</i> , 2017, 194, 73-82.	2.7	15

#	ARTICLE	IF	CITATIONS
55	Long-term mortality and prehospital tirofiban treatment in patients with ST elevation myocardial infarction. <i>Heart</i> , 2017, 103, 1515-1520.	2.9	19
56	Association of Traditional Cardiovascular Risk Factors With Venous Thromboembolism. <i>Circulation</i> , 2017, 135, 7-16.	1.6	114
57	Observational Study of Platelet Reactivity in Patients Presenting With ST-Segment Elevation Myocardial Infarction Due to Coronary Stent Thrombosis Undergoing Primary Percutaneous Coronary Intervention. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 2548-2556.	2.9	8
58	Fibrin clot formation and fibrinolysis in patients with a history of coronary stent thrombosis. <i>Thrombosis Research</i> , 2016, 143, 58-62.	1.7	1
59	Design and Rationale of the DUAL PCI Trial: A Prospective, Randomized, Phase 3b Study Comparing the Safety and Efficacy of Dual Antithrombotic Therapy With Dabigatran Etxilate Versus Warfarin Triple Therapy in Patients With Nonvalvular Atrial Fibrillation Who Have Undergone Percutaneous Coronary Intervention With Stenting. <i>Clinical Cardiology</i> , 2016, 39, 555-564.	1.8	65
60	P2Y12 receptor inhibition and effect of morphine in patients undergoing primary PCI for ST-segment elevation myocardial infarction. <i>Thrombosis and Haemostasis</i> , 2016, 116, 369-378.	3.4	97
61	Interaction of Hereditary Thrombophilia and Traditional Cardiovascular Risk Factors on the Risk of Arterial Thromboembolism. <i>Circulation: Cardiovascular Genetics</i> , 2016, 9, 79-85.	5.1	20
62	ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting. <i>European Heart Journal</i> , 2015, 36, 1252-1263.	2.2	366
63	Management of the patient with an acute coronary syndrome using oral anticoagulation. <i>Netherlands Heart Journal</i> , 2015, 23, 407-414.	0.8	4
64	Bleeding and stent thrombosis on P2Y ₁₂ -inhibitors: collaborative analysis on the role of platelet reactivity for risk stratification after percutaneous coronary intervention. <i>European Heart Journal</i> , 2015, 36, 1762-1771.	2.2	297
65	Ticagrelor or prasugrel versus clopidogrel in elderly patients with an acute coronary syndrome: Optimization of antiplatelet treatment in patients 70years and older rationale and design of the POPular AGE study. <i>American Heart Journal</i> , 2015, 170, 981-985.e1.	2.7	43
66	The role of perioperative antiplatelet therapy and platelet reactivity testing in carotid revascularization: overview of the evidence. <i>Journal of Cardiovascular Surgery</i> , 2015, 56, 165-75.	0.6	2
67	CYP2C19 genotype-guided antiplatelet therapy in ST-segment elevation myocardial infarction patients Rationale and design of the Patient Outcome after primary PCI (POPular) Genetics study. <i>American Heart Journal</i> , 2014, 168, 16-22.e1.	2.7	71
68	Optimizing Antithrombotic Therapy After Coronary Stent Implantation in Patients on Chronic Oral Anticoagulation. <i>Journal of Cardiovascular Translational Research</i> , 2014, 7, 64-71.	2.4	2
69	Dual Antiplatelet Therapy in the Anticoagulated Patient Undergoing Percutaneous Coronary Intervention Risks, Benefits, and Unanswered Questions. <i>Current Cardiology Reports</i> , 2014, 16, 548.	2.9	2
70	New oral anticoagulants after acute coronary syndrome. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 141-150.	1.7	2
71	Platelet Function Testing and Tailored Antiplatelet Therapy. <i>Journal of Cardiovascular Translational Research</i> , 2013, 6, 316-328.	2.4	34
72	The effect of prehospital glycoprotein IIb/IIIa inhibitors on angiographic outcome in STEMI patients who are candidates for primary PCI. <i>Catheterization and Cardiovascular Interventions</i> , 2012, 79, 956-964.	1.7	21

#	ARTICLE	IF	CITATIONS
73	Variability in on-treatment platelet reactivity explained by CYP2C19*2 genotype is modest in clopidogrel pretreated patients undergoing coronary stenting. <i>Heart</i> , 2011, 97, 1239-1244.	2.9	72
74	High-dose tirofiban pretreatment reduces the need for bail-out study medication in patients with ST-segment elevation myocardial infarction: results of a subgroup analysis of the On-TIME 2 trial. <i>Heart</i> , 2011, 97, 106-111.	2.9	11
75	Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction. <i>Journal of Thrombosis and Haemostasis</i> , 2009, 7, 1612-1618.	3.8	33
76	Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty (On-TIME 2): a multicentre, double-blind, randomised controlled trial. <i>Lancet</i> , The, 2008, 372, 537-546.	13.7	431